OmniStar Financial Group Inc. Acquires 11,837 Shares of Johnson & Johnson $JNJ

OmniStar Financial Group Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 100.7% in the second quarter, HoldingsChannel.com reports. The firm owned 23,595 shares of the company’s stock after buying an additional 11,837 shares during the quarter. Johnson & Johnson comprises about 2.7% of OmniStar Financial Group Inc.’s investment portfolio, making the stock its 5th largest holding. OmniStar Financial Group Inc.’s holdings in Johnson & Johnson were worth $3,604,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. Wealth Group Ltd. acquired a new position in Johnson & Johnson in the first quarter valued at $218,000. Smart Money Group LLC grew its holdings in shares of Johnson & Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock worth $1,109,000 after purchasing an additional 407 shares during the last quarter. Frederick Financial Consultants LLC lifted its holdings in shares of Johnson & Johnson by 3.8% in the 1st quarter. Frederick Financial Consultants LLC now owns 2,233 shares of the company’s stock valued at $370,000 after purchasing an additional 82 shares during the last quarter. Finally, Members Trust Co lifted its holdings in shares of Johnson & Johnson by 13.2% in the 1st quarter. Members Trust Co now owns 8,658 shares of the company’s stock valued at $1,436,000 after purchasing an additional 1,009 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $196.00 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average is $185.81 and its two-hundred day moving average is $169.94. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $197.18. The firm has a market capitalization of $472.22 billion, a PE ratio of 18.92, a P/E/G ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday, October 9th. Raymond James Financial raised their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Finally, Scotiabank initiated coverage on shares of Johnson & Johnson in a report on Thursday. They issued a “sector outperform” rating and a $230.00 target price for the company. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.